Emerging toxicities in the treatment of non-small cell lung cancer: Ocular disorders

Francesco Agustoni, Marco Platania, Milena Vitali, Nicoletta Zilembo, Eva Haspinger, Valentina Sinno, Rosaria Gallucci, Filippo De Braud, Marina Chiara Garassino

Research output: Contribution to journalArticle

Abstract

The treatment of advanced disease (stage IIIb and IV) of non-small cell lung cancer (NSCLC) is based on systemic treatment with platinum-based chemotherapy or biological compounds depending on the disease molecular profile. In the last few years, intensive investigational efforts in anticancer therapy have led to the registration of new active chemotherapeutic agents, combination regimens, and biological drugs, expanding choices for customizing individual treatment. However, the introduction of new drugs in the clinical setting has led to several new toxicities, creating some difficulties in daily management. Among these, ocular toxicity is generally overlooked as more common toxicities such as myelosuppression, stomatitis, diarrhea, vomiting, "hand-foot syndrome", and neurological alterations attract greater attention. Ophthalmic complications from cytotoxic chemotherapeutics are rare, transient, and of mild/moderate intensity but irreversible acute disorders are possible. The best way to prevent potential irreversible visual complications is an awareness of the potential for ocular toxicity because dose reductions or early drug cessation can prevent serious ocular complications in the majority of cases. However, given the novelty of many therapeutic agents and the complexity of ocular pathology, oncologists may be unfamiliar with these adverse effects of anticancer therapy. Although toxicities from chemotherapy are generally intense but short lasting, toxicities related to targeted drugs are often milder but longer lasting and can persist throughout treatment. Here we review the principal clinical presentations of ocular toxicity arising from chemotherapy [1-3], target therapies [4], and newly developed drugs and provide some recommendations for monitoring and management of ocular toxicity.

Original languageEnglish
Pages (from-to)197-203
Number of pages7
JournalCancer Treatment Reviews
Volume40
Issue number1
DOIs
Publication statusPublished - Feb 2014

Fingerprint

Eye Neoplasms
Non-Small Cell Lung Carcinoma
Pharmaceutical Preparations
Therapeutics
Drug Therapy
Hand-Foot Syndrome
Stomatitis
Platinum
Vomiting
Diarrhea
Pathology

Keywords

  • Chemotherapy
  • Non-small-cell lung cancer
  • Ocular toxicity
  • Ophthalmology
  • Target therapies

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Emerging toxicities in the treatment of non-small cell lung cancer : Ocular disorders. / Agustoni, Francesco; Platania, Marco; Vitali, Milena; Zilembo, Nicoletta; Haspinger, Eva; Sinno, Valentina; Gallucci, Rosaria; De Braud, Filippo; Garassino, Marina Chiara.

In: Cancer Treatment Reviews, Vol. 40, No. 1, 02.2014, p. 197-203.

Research output: Contribution to journalArticle

Agustoni, Francesco ; Platania, Marco ; Vitali, Milena ; Zilembo, Nicoletta ; Haspinger, Eva ; Sinno, Valentina ; Gallucci, Rosaria ; De Braud, Filippo ; Garassino, Marina Chiara. / Emerging toxicities in the treatment of non-small cell lung cancer : Ocular disorders. In: Cancer Treatment Reviews. 2014 ; Vol. 40, No. 1. pp. 197-203.
@article{35d8a90df7db465c97f3249d8d3a2d32,
title = "Emerging toxicities in the treatment of non-small cell lung cancer: Ocular disorders",
abstract = "The treatment of advanced disease (stage IIIb and IV) of non-small cell lung cancer (NSCLC) is based on systemic treatment with platinum-based chemotherapy or biological compounds depending on the disease molecular profile. In the last few years, intensive investigational efforts in anticancer therapy have led to the registration of new active chemotherapeutic agents, combination regimens, and biological drugs, expanding choices for customizing individual treatment. However, the introduction of new drugs in the clinical setting has led to several new toxicities, creating some difficulties in daily management. Among these, ocular toxicity is generally overlooked as more common toxicities such as myelosuppression, stomatitis, diarrhea, vomiting, {"}hand-foot syndrome{"}, and neurological alterations attract greater attention. Ophthalmic complications from cytotoxic chemotherapeutics are rare, transient, and of mild/moderate intensity but irreversible acute disorders are possible. The best way to prevent potential irreversible visual complications is an awareness of the potential for ocular toxicity because dose reductions or early drug cessation can prevent serious ocular complications in the majority of cases. However, given the novelty of many therapeutic agents and the complexity of ocular pathology, oncologists may be unfamiliar with these adverse effects of anticancer therapy. Although toxicities from chemotherapy are generally intense but short lasting, toxicities related to targeted drugs are often milder but longer lasting and can persist throughout treatment. Here we review the principal clinical presentations of ocular toxicity arising from chemotherapy [1-3], target therapies [4], and newly developed drugs and provide some recommendations for monitoring and management of ocular toxicity.",
keywords = "Chemotherapy, Non-small-cell lung cancer, Ocular toxicity, Ophthalmology, Target therapies",
author = "Francesco Agustoni and Marco Platania and Milena Vitali and Nicoletta Zilembo and Eva Haspinger and Valentina Sinno and Rosaria Gallucci and {De Braud}, Filippo and Garassino, {Marina Chiara}",
year = "2014",
month = "2",
doi = "10.1016/j.ctrv.2013.05.005",
language = "English",
volume = "40",
pages = "197--203",
journal = "Cancer Treatment Reviews",
issn = "0305-7372",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Emerging toxicities in the treatment of non-small cell lung cancer

T2 - Ocular disorders

AU - Agustoni, Francesco

AU - Platania, Marco

AU - Vitali, Milena

AU - Zilembo, Nicoletta

AU - Haspinger, Eva

AU - Sinno, Valentina

AU - Gallucci, Rosaria

AU - De Braud, Filippo

AU - Garassino, Marina Chiara

PY - 2014/2

Y1 - 2014/2

N2 - The treatment of advanced disease (stage IIIb and IV) of non-small cell lung cancer (NSCLC) is based on systemic treatment with platinum-based chemotherapy or biological compounds depending on the disease molecular profile. In the last few years, intensive investigational efforts in anticancer therapy have led to the registration of new active chemotherapeutic agents, combination regimens, and biological drugs, expanding choices for customizing individual treatment. However, the introduction of new drugs in the clinical setting has led to several new toxicities, creating some difficulties in daily management. Among these, ocular toxicity is generally overlooked as more common toxicities such as myelosuppression, stomatitis, diarrhea, vomiting, "hand-foot syndrome", and neurological alterations attract greater attention. Ophthalmic complications from cytotoxic chemotherapeutics are rare, transient, and of mild/moderate intensity but irreversible acute disorders are possible. The best way to prevent potential irreversible visual complications is an awareness of the potential for ocular toxicity because dose reductions or early drug cessation can prevent serious ocular complications in the majority of cases. However, given the novelty of many therapeutic agents and the complexity of ocular pathology, oncologists may be unfamiliar with these adverse effects of anticancer therapy. Although toxicities from chemotherapy are generally intense but short lasting, toxicities related to targeted drugs are often milder but longer lasting and can persist throughout treatment. Here we review the principal clinical presentations of ocular toxicity arising from chemotherapy [1-3], target therapies [4], and newly developed drugs and provide some recommendations for monitoring and management of ocular toxicity.

AB - The treatment of advanced disease (stage IIIb and IV) of non-small cell lung cancer (NSCLC) is based on systemic treatment with platinum-based chemotherapy or biological compounds depending on the disease molecular profile. In the last few years, intensive investigational efforts in anticancer therapy have led to the registration of new active chemotherapeutic agents, combination regimens, and biological drugs, expanding choices for customizing individual treatment. However, the introduction of new drugs in the clinical setting has led to several new toxicities, creating some difficulties in daily management. Among these, ocular toxicity is generally overlooked as more common toxicities such as myelosuppression, stomatitis, diarrhea, vomiting, "hand-foot syndrome", and neurological alterations attract greater attention. Ophthalmic complications from cytotoxic chemotherapeutics are rare, transient, and of mild/moderate intensity but irreversible acute disorders are possible. The best way to prevent potential irreversible visual complications is an awareness of the potential for ocular toxicity because dose reductions or early drug cessation can prevent serious ocular complications in the majority of cases. However, given the novelty of many therapeutic agents and the complexity of ocular pathology, oncologists may be unfamiliar with these adverse effects of anticancer therapy. Although toxicities from chemotherapy are generally intense but short lasting, toxicities related to targeted drugs are often milder but longer lasting and can persist throughout treatment. Here we review the principal clinical presentations of ocular toxicity arising from chemotherapy [1-3], target therapies [4], and newly developed drugs and provide some recommendations for monitoring and management of ocular toxicity.

KW - Chemotherapy

KW - Non-small-cell lung cancer

KW - Ocular toxicity

KW - Ophthalmology

KW - Target therapies

UR - http://www.scopus.com/inward/record.url?scp=84887114679&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887114679&partnerID=8YFLogxK

U2 - 10.1016/j.ctrv.2013.05.005

DO - 10.1016/j.ctrv.2013.05.005

M3 - Article

C2 - 23850197

AN - SCOPUS:84887114679

VL - 40

SP - 197

EP - 203

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

SN - 0305-7372

IS - 1

ER -